TrialBritish journal of clinical pharmacology2017

Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects.

Adeep Puri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.